A citation-based method for searching scientific literature

Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
Times Cited: 776



Krishnansu S Tewari, Robert A Burger, Danielle Enserro, Barbara M Norquist, Elizabeth M Swisher, Mark F Brady, Michael A Bookman, Gini F Fleming, Helen Huang, Howard D Homesley, Jeffrey M Fowler, Benjamin E Greer, Matthew Boente, Sharon X Liang, Chenglin Ye, Carlos Bais, Leslie M Randall, John K Chan, J Stuart Ferriss, Robert L Coleman, Carol Aghajanian, Thomas J Herzog, Philip J DiSaia, Larry J Copeland, Robert S Mannel, Michael J Birrer, Bradley J Monk. J Clin Oncol 2019
Times Cited: 104




List of shared articles



Times cited

The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
Shiru Liu, Lawrence Kasherman, Rouhi Fazelzad, Lisa Wang, Genevieve Bouchard-Fortier, Stephanie Lheureux, Monika K Krzyzanowska. Gynecol Oncol 2021
1

Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer.
Olivia Le Saux, Hélène Vanacker, Fatma Guermazi, Mélodie Carbonnaux, Clémence Roméo, Louis Larrouquère, Olivier Trédan, Isabelle Ray-Coquard. Future Oncol 2021
0

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Simona Frezzini, Germana Tognon, Grazia Artioli, Angiolo Gadducci, Rossella Lauria,[...]. Int J Gynecol Cancer 2021
1

The impact of body composition on treatment in ovarian cancer: a current insight.
Veronica McSharry, Kate Glennon, Amy Mullee, Donal Brennan. Expert Rev Clin Pharmacol 2021
0

Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Angeles Alvarez Secord, David M O'Malley, Anil K Sood, Shannon N Westin, Joyce F Liu. Gynecol Oncol 2021
0

The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment.
Mark A Eckert, Carlos Orozco, Jason Xiao, Melissa Javellana, Ernst Lengyel. Cancers (Basel) 2021
0

Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer.
Paola Todeschini, Elisa Salviato, Chiara Romani, Vittoria Raimondi, Francesco Ciccarese, Federico Ferrari, Germana Tognon, Sergio Marchini, Maurizio D'Incalci, Laura Zanotti,[...]. Cancers (Basel) 2021
0

Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052).
Se Ik Kim, Jeong Won Lee, Kidong Kim, Maria Lee, Jigeun Yoo, Min Chul Choi, Suhyun Hwangbo, Young Hwa Kwak, Jong Min Lee, So Jin Shin,[...]. J Gynecol Oncol 2021
0

Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
Katherine C Kurnit, Gini F Fleming, Ernst Lengyel. Obstet Gynecol 2021
4

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
J A Ledermann, A C Embleton-Thirsk, T J Perren, G C Jayson, G J S Rustin, S B Kaye, H Hirte, A Oza, M Vaughan, M Friedlander,[...]. ESMO Open 2021
1

Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer.
Angela Cho, Jeong-Yeol Park, Shin-Wha Lee, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim. Arch Gynecol Obstet 2021
0

Bevacizumab in advanced endometrial cancer.
Maria M Rubinstein, Shannan Dickinson, Priyanka Narayan, Qin Zhou, Alexia Iasonos, Weining Ma, Yulia Lakhman, Vicky Makker. Gynecol Oncol 2021
1

A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA.
Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys. Acta Clin Belg 2021
0

Latest clinical evidence of maintenance therapy in ovarian cancer.
Christine S Walsh. Curr Opin Obstet Gynecol 2020
11

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Josep Garcia, Herbert I Hurwitz, Alan B Sandler, David Miles, Robert L Coleman, Regula Deurloo, Olivier L Chinot. Cancer Treat Rev 2020
101